IL
Illinois House Bill HB3256

Illinois 2023-2024 Regular Session

Illinois House Bill HB3256 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3256 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED: New Act5 ILCS 140/7.5 Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act from inspection and copying under the Act. Contains a severability provision. Effective July 1, 2023. LRB103 27492 CPF 53866 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3256 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED: New Act5 ILCS 140/7.5 New Act 5 ILCS 140/7.5 Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act from inspection and copying under the Act. Contains a severability provision. Effective July 1, 2023. LRB103 27492 CPF 53866 b LRB103 27492 CPF 53866 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3256 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED:
33 New Act5 ILCS 140/7.5 New Act 5 ILCS 140/7.5
44 New Act
55 5 ILCS 140/7.5
66 Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act from inspection and copying under the Act. Contains a severability provision. Effective July 1, 2023.
77 LRB103 27492 CPF 53866 b LRB103 27492 CPF 53866 b
88 LRB103 27492 CPF 53866 b
99 A BILL FOR
1010 HB3256LRB103 27492 CPF 53866 b HB3256 LRB103 27492 CPF 53866 b
1111 HB3256 LRB103 27492 CPF 53866 b
1212 1 AN ACT concerning health.
1313 2 Be it enacted by the People of the State of Illinois,
1414 3 represented in the General Assembly:
1515 4 Section 1. Short title. This Act may be cited as the
1616 5 Affordable Drug Manufacturing Act.
1717 6 Section 5. Definitions. In this Act:
1818 7 "Department" means the Department of Public Health.
1919 8 "Eligible prescription drug" means a prescription drug
2020 9 that is not under patent or a biological product, as defined in
2121 10 42 U.S.C. 262(i), that is not under patent.
2222 11 "Generic prescription drug" means a drug that is approved
2323 12 pursuant to an application referencing an eligible
2424 13 prescription drug that is submitted under subsection (j) of
2525 14 Section 505 of the Federal Food, Drug, and Cosmetic Act (21
2626 15 U.S.C. 355(j)) or under subsection (k) of Section 351 of the
2727 16 federal Public Health Service Act (42 U.S.C. 262(k)).
2828 17 "Partnerships" include, but are not limited to, agreements
2929 18 for the procurement of generic prescription drugs by way of
3030 19 contracts or purchasing by a payor, State governmental agency,
3131 20 group purchasing organization, nonprofit organization, or
3232 21 other entity.
3333 22 "Provider" means a hospital licensed under the Hospital
3434 23 Licensing Act or organized under the University of Illinois
3535
3636
3737
3838 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3256 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED:
3939 New Act5 ILCS 140/7.5 New Act 5 ILCS 140/7.5
4040 New Act
4141 5 ILCS 140/7.5
4242 Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act from inspection and copying under the Act. Contains a severability provision. Effective July 1, 2023.
4343 LRB103 27492 CPF 53866 b LRB103 27492 CPF 53866 b
4444 LRB103 27492 CPF 53866 b
4545 A BILL FOR
4646
4747
4848
4949
5050
5151 New Act
5252 5 ILCS 140/7.5
5353
5454
5555
5656 LRB103 27492 CPF 53866 b
5757
5858
5959
6060
6161
6262
6363
6464
6565
6666 HB3256 LRB103 27492 CPF 53866 b
6767
6868
6969 HB3256- 2 -LRB103 27492 CPF 53866 b HB3256 - 2 - LRB103 27492 CPF 53866 b
7070 HB3256 - 2 - LRB103 27492 CPF 53866 b
7171 1 Hospital Act, a skilled nursing facility as that term is
7272 2 defined under Section 2 of the Comprehensive Health Insurance
7373 3 Plan Act, a comprehensive outpatient rehabilitation facility,
7474 4 a home health agency as that term is defined under Section 2.04
7575 5 of the Home Health, Home Services, and Home Nursing Agency
7676 6 Licensing Act, a hospice as that term is defined under Section
7777 7 2 of the Comprehensive Health Insurance Plan Act, a public
7878 8 health clinic as that term is defined under Section 6-101 of
7979 9 the Local Governmental and Governmental Employees Tort
8080 10 Immunity Act, or a rehabilitation agency.
8181 11 "Supplier" means a physician, surgeon, or other health
8282 12 care practitioner or an entity other than a provider that
8383 13 furnishes health care services.
8484 14 Section 10. Cost of prescription drugs; partnerships.
8585 15 (a) The Department shall enter into partnerships
8686 16 consistent with subsection (b) of Section 15, in consultation
8787 17 with other State agencies as necessary, to increase
8888 18 competition, lower prices, and address shortages in the market
8989 19 for generic prescription drugs, reduce the cost of generic
9090 20 prescription drugs for public and private purchasers,
9191 21 taxpayers, and consumers, and increase patient access to
9292 22 affordable generic prescription drugs.
9393 23 (b) Subject appropriation by the General Assembly for this
9494 24 purpose, the Department may hire staff to oversee and
9595 25 project-manage the partnerships for manufacturing or
9696
9797
9898
9999
100100
101101 HB3256 - 2 - LRB103 27492 CPF 53866 b
102102
103103
104104 HB3256- 3 -LRB103 27492 CPF 53866 b HB3256 - 3 - LRB103 27492 CPF 53866 b
105105 HB3256 - 3 - LRB103 27492 CPF 53866 b
106106 1 distribution of generic prescription drugs.
107107 2 Section 15. Generic prescription drug prices.
108108 3 (a) The Department shall enter into partnerships resulting
109109 4 in the production or distribution of generic prescription
110110 5 drugs with the intent that these generic prescription drugs be
111111 6 made widely available to public and private purchasers,
112112 7 providers and suppliers, and pharmacies licensed under the
113113 8 Pharmacy Practice Act, as appropriate. The generic
114114 9 prescription drugs shall be produced or distributed by a drug
115115 10 company or generic prescription drug manufacturer that is
116116 11 registered with the United States Food and Drug
117117 12 Administration.
118118 13 (b) The Department shall comply with the following
119119 14 requirements when entering into partnerships or setting prices
120120 15 for generic prescription drugs:
121121 16 (1) The Department shall only enter into partnerships
122122 17 under subsection (a) to produce a generic prescription
123123 18 drug at a price that results in savings, target failures
124124 19 in the market for generic prescription drugs, and improve
125125 20 patient access to affordable medications.
126126 21 (2) For generic prescription drugs prioritized in
127127 22 accordance with the criteria listed in paragraph (5), the
128128 23 Department shall determine if viable pathways exist for
129129 24 partnerships to manufacture or distribute generic
130130 25 prescription drugs by examining the relevant legal,
131131
132132
133133
134134
135135
136136 HB3256 - 3 - LRB103 27492 CPF 53866 b
137137
138138
139139 HB3256- 4 -LRB103 27492 CPF 53866 b HB3256 - 4 - LRB103 27492 CPF 53866 b
140140 HB3256 - 4 - LRB103 27492 CPF 53866 b
141141 1 market, policy, and regulatory factors.
142142 2 (3) The Department shall consider the following, if
143143 3 applicable, when setting the price of a generic
144144 4 prescription drug under this Section:
145145 5 (A) United States Food and Drug Administration
146146 6 user fees.
147147 7 (B) Abbreviated new drug application acquisition
148148 8 costs, amortized over a 5-year period.
149149 9 (C) Mandatory rebates.
150150 10 (D) Total contracting and production costs for the
151151 11 generic prescription drug, including a reasonable
152152 12 amount for administrative, operating, and
153153 13 rate-of-return expenses of the drug company or generic
154154 14 prescription drug manufacturer.
155155 15 (E) Research and development costs attributed to
156156 16 the generic prescription drug over a 5-year period.
157157 17 (F) Other initial start-up costs, amortized over a
158158 18 5-year period.
159159 19 (4) Each generic prescription drug shall be made
160160 20 available to providers, patients, and purchasers at a
161161 21 transparent price and without rebates, other than
162162 22 federally required rebates.
163163 23 (5) The Department shall prioritize the selection of
164164 24 generic prescription drugs that have the greatest impact
165165 25 on lowering drug costs to patients, increasing competition
166166 26 and addressing shortages in the prescription drug market,
167167
168168
169169
170170
171171
172172 HB3256 - 4 - LRB103 27492 CPF 53866 b
173173
174174
175175 HB3256- 5 -LRB103 27492 CPF 53866 b HB3256 - 5 - LRB103 27492 CPF 53866 b
176176 HB3256 - 5 - LRB103 27492 CPF 53866 b
177177 1 improving public health, or reducing the cost of
178178 2 prescription drugs to public and private purchasers.
179179 3 (c) In identifying generic prescription drugs to be
180180 4 produced, the Department shall consider pharmacy spending data
181181 5 from Medicaid and other entities for which the State pays the
182182 6 cost of generic prescription drugs.
183183 7 The partnerships entered into under subsection (a) shall
184184 8 include the production of at least one form of insulin,
185185 9 provided that a viable pathway for manufacturing a more
186186 10 affordable form of insulin exists.
187187 11 The Department shall prioritize generic prescription drugs
188188 12 for chronic and high-cost conditions and shall consider
189189 13 prioritizing those that can be delivered through mail order.
190190 14 (d) The Department shall consult with all of the following
191191 15 public and private purchasers to assist in developing a list
192192 16 of generic prescription drugs to be manufactured or
193193 17 distributed through partnerships and to determine the volume
194194 18 of each generic prescription drug that can be procured over a
195195 19 multiyear period to support a market for a lower-cost generic
196196 20 prescription drug:
197197 21 (1) Any public agency that is a purchaser.
198198 22 (2) Health insurers holding a valid outstanding
199199 23 certificate of authority from the Director of Insurance.
200200 24 (3) Hospitals.
201201 25 (4) Pharmacy benefit managers.
202202 26 (e) Before entering into a partnership under subsection
203203
204204
205205
206206
207207
208208 HB3256 - 5 - LRB103 27492 CPF 53866 b
209209
210210
211211 HB3256- 6 -LRB103 27492 CPF 53866 b HB3256 - 6 - LRB103 27492 CPF 53866 b
212212 HB3256 - 6 - LRB103 27492 CPF 53866 b
213213 1 (a), the Department shall determine minimum thresholds for
214214 2 procurement of an entity's expected volume of a targeted
215215 3 generic prescription drug from the company or manufacturer
216216 4 over a multiyear period.
217217 5 (f) The entities listed in paragraphs (2) through (5) of
218218 6 subsection (d) shall not be required to purchase prescription
219219 7 drugs from the Department or from entities that contract or
220220 8 partner with the Department under this Act.
221221 9 (g) The Department is not required to consult with every
222222 10 entity listed in paragraphs (2) through (5) of subsection (d)
223223 11 so long as purchaser engagement includes a reasonable
224224 12 representation from those groups.
225225 13 Section 20. Feasibility report.
226226 14 (a) On or before July 1, 2025, the Department shall submit
227227 15 a report to the General Assembly that assesses the feasibility
228228 16 of the Department directly manufacturing generic prescription
229229 17 drugs and selling generic prescription drugs at a fair price.
230230 18 The report shall include an analysis of governance structure
231231 19 options for manufacturing functions, including chartering a
232232 20 private organization, public-private partnership, or public
233233 21 board of directors.
234234 22 (b) This Section is repealed on January 1, 2027.
235235 23 Section 25. Status and analysis report.
236236 24 (a) On or before July 1, 2024, the Department shall submit
237237
238238
239239
240240
241241
242242 HB3256 - 6 - LRB103 27492 CPF 53866 b
243243
244244
245245 HB3256- 7 -LRB103 27492 CPF 53866 b HB3256 - 7 - LRB103 27492 CPF 53866 b
246246 HB3256 - 7 - LRB103 27492 CPF 53866 b
247247 1 a report to the General Assembly with:
248248 2 (1) a description of the status of all drugs targeted
249249 3 under this Act; and
250250 4 (2) an analysis of how the activities of the
251251 5 Department may impact competition, access to targeted
252252 6 drugs, the costs of those drugs, and the costs of generic
253253 7 prescription drugs for public and private purchasers.
254254 8 (b) This Section is repealed on January 1, 2028.
255255 9 Section 30. Nonpublic information; disclosure.
256256 10 Notwithstanding any other provision of law, all nonpublic
257257 11 information and documents obtained under this Act shall not be
258258 12 required to be disclosed pursuant to the Freedom of
259259 13 Information Act.
260260 14 Section 35. The Freedom of Information Act is amended by
261261 15 changing Section 7.5 as follows:
262262 16 (5 ILCS 140/7.5)
263263 17 Sec. 7.5. Statutory exemptions. To the extent provided for
264264 18 by the statutes referenced below, the following shall be
265265 19 exempt from inspection and copying:
266266 20 (a) All information determined to be confidential
267267 21 under Section 4002 of the Technology Advancement and
268268 22 Development Act.
269269 23 (b) Library circulation and order records identifying
270270
271271
272272
273273
274274
275275 HB3256 - 7 - LRB103 27492 CPF 53866 b
276276
277277
278278 HB3256- 8 -LRB103 27492 CPF 53866 b HB3256 - 8 - LRB103 27492 CPF 53866 b
279279 HB3256 - 8 - LRB103 27492 CPF 53866 b
280280 1 library users with specific materials under the Library
281281 2 Records Confidentiality Act.
282282 3 (c) Applications, related documents, and medical
283283 4 records received by the Experimental Organ Transplantation
284284 5 Procedures Board and any and all documents or other
285285 6 records prepared by the Experimental Organ Transplantation
286286 7 Procedures Board or its staff relating to applications it
287287 8 has received.
288288 9 (d) Information and records held by the Department of
289289 10 Public Health and its authorized representatives relating
290290 11 to known or suspected cases of sexually transmissible
291291 12 disease or any information the disclosure of which is
292292 13 restricted under the Illinois Sexually Transmissible
293293 14 Disease Control Act.
294294 15 (e) Information the disclosure of which is exempted
295295 16 under Section 30 of the Radon Industry Licensing Act.
296296 17 (f) Firm performance evaluations under Section 55 of
297297 18 the Architectural, Engineering, and Land Surveying
298298 19 Qualifications Based Selection Act.
299299 20 (g) Information the disclosure of which is restricted
300300 21 and exempted under Section 50 of the Illinois Prepaid
301301 22 Tuition Act.
302302 23 (h) Information the disclosure of which is exempted
303303 24 under the State Officials and Employees Ethics Act, and
304304 25 records of any lawfully created State or local inspector
305305 26 general's office that would be exempt if created or
306306
307307
308308
309309
310310
311311 HB3256 - 8 - LRB103 27492 CPF 53866 b
312312
313313
314314 HB3256- 9 -LRB103 27492 CPF 53866 b HB3256 - 9 - LRB103 27492 CPF 53866 b
315315 HB3256 - 9 - LRB103 27492 CPF 53866 b
316316 1 obtained by an Executive Inspector General's office under
317317 2 that Act.
318318 3 (i) Information contained in a local emergency energy
319319 4 plan submitted to a municipality in accordance with a
320320 5 local emergency energy plan ordinance that is adopted
321321 6 under Section 11-21.5-5 of the Illinois Municipal Code.
322322 7 (j) Information and data concerning the distribution
323323 8 of surcharge moneys collected and remitted by carriers
324324 9 under the Emergency Telephone System Act.
325325 10 (k) Law enforcement officer identification information
326326 11 or driver identification information compiled by a law
327327 12 enforcement agency or the Department of Transportation
328328 13 under Section 11-212 of the Illinois Vehicle Code.
329329 14 (l) Records and information provided to a residential
330330 15 health care facility resident sexual assault and death
331331 16 review team or the Executive Council under the Abuse
332332 17 Prevention Review Team Act.
333333 18 (m) Information provided to the predatory lending
334334 19 database created pursuant to Article 3 of the Residential
335335 20 Real Property Disclosure Act, except to the extent
336336 21 authorized under that Article.
337337 22 (n) Defense budgets and petitions for certification of
338338 23 compensation and expenses for court appointed trial
339339 24 counsel as provided under Sections 10 and 15 of the
340340 25 Capital Crimes Litigation Act. This subsection (n) shall
341341 26 apply until the conclusion of the trial of the case, even
342342
343343
344344
345345
346346
347347 HB3256 - 9 - LRB103 27492 CPF 53866 b
348348
349349
350350 HB3256- 10 -LRB103 27492 CPF 53866 b HB3256 - 10 - LRB103 27492 CPF 53866 b
351351 HB3256 - 10 - LRB103 27492 CPF 53866 b
352352 1 if the prosecution chooses not to pursue the death penalty
353353 2 prior to trial or sentencing.
354354 3 (o) Information that is prohibited from being
355355 4 disclosed under Section 4 of the Illinois Health and
356356 5 Hazardous Substances Registry Act.
357357 6 (p) Security portions of system safety program plans,
358358 7 investigation reports, surveys, schedules, lists, data, or
359359 8 information compiled, collected, or prepared by or for the
360360 9 Department of Transportation under Sections 2705-300 and
361361 10 2705-616 of the Department of Transportation Law of the
362362 11 Civil Administrative Code of Illinois, the Regional
363363 12 Transportation Authority under Section 2.11 of the
364364 13 Regional Transportation Authority Act, or the St. Clair
365365 14 County Transit District under the Bi-State Transit Safety
366366 15 Act.
367367 16 (q) Information prohibited from being disclosed by the
368368 17 Personnel Record Review Act.
369369 18 (r) Information prohibited from being disclosed by the
370370 19 Illinois School Student Records Act.
371371 20 (s) Information the disclosure of which is restricted
372372 21 under Section 5-108 of the Public Utilities Act.
373373 22 (t) All identified or deidentified health information
374374 23 in the form of health data or medical records contained
375375 24 in, stored in, submitted to, transferred by, or released
376376 25 from the Illinois Health Information Exchange, and
377377 26 identified or deidentified health information in the form
378378
379379
380380
381381
382382
383383 HB3256 - 10 - LRB103 27492 CPF 53866 b
384384
385385
386386 HB3256- 11 -LRB103 27492 CPF 53866 b HB3256 - 11 - LRB103 27492 CPF 53866 b
387387 HB3256 - 11 - LRB103 27492 CPF 53866 b
388388 1 of health data and medical records of the Illinois Health
389389 2 Information Exchange in the possession of the Illinois
390390 3 Health Information Exchange Office due to its
391391 4 administration of the Illinois Health Information
392392 5 Exchange. The terms "identified" and "deidentified" shall
393393 6 be given the same meaning as in the Health Insurance
394394 7 Portability and Accountability Act of 1996, Public Law
395395 8 104-191, or any subsequent amendments thereto, and any
396396 9 regulations promulgated thereunder.
397397 10 (u) Records and information provided to an independent
398398 11 team of experts under the Developmental Disability and
399399 12 Mental Health Safety Act (also known as Brian's Law).
400400 13 (v) Names and information of people who have applied
401401 14 for or received Firearm Owner's Identification Cards under
402402 15 the Firearm Owners Identification Card Act or applied for
403403 16 or received a concealed carry license under the Firearm
404404 17 Concealed Carry Act, unless otherwise authorized by the
405405 18 Firearm Concealed Carry Act; and databases under the
406406 19 Firearm Concealed Carry Act, records of the Concealed
407407 20 Carry Licensing Review Board under the Firearm Concealed
408408 21 Carry Act, and law enforcement agency objections under the
409409 22 Firearm Concealed Carry Act.
410410 23 (v-5) Records of the Firearm Owner's Identification
411411 24 Card Review Board that are exempted from disclosure under
412412 25 Section 10 of the Firearm Owners Identification Card Act.
413413 26 (w) Personally identifiable information which is
414414
415415
416416
417417
418418
419419 HB3256 - 11 - LRB103 27492 CPF 53866 b
420420
421421
422422 HB3256- 12 -LRB103 27492 CPF 53866 b HB3256 - 12 - LRB103 27492 CPF 53866 b
423423 HB3256 - 12 - LRB103 27492 CPF 53866 b
424424 1 exempted from disclosure under subsection (g) of Section
425425 2 19.1 of the Toll Highway Act.
426426 3 (x) Information which is exempted from disclosure
427427 4 under Section 5-1014.3 of the Counties Code or Section
428428 5 8-11-21 of the Illinois Municipal Code.
429429 6 (y) Confidential information under the Adult
430430 7 Protective Services Act and its predecessor enabling
431431 8 statute, the Elder Abuse and Neglect Act, including
432432 9 information about the identity and administrative finding
433433 10 against any caregiver of a verified and substantiated
434434 11 decision of abuse, neglect, or financial exploitation of
435435 12 an eligible adult maintained in the Registry established
436436 13 under Section 7.5 of the Adult Protective Services Act.
437437 14 (z) Records and information provided to a fatality
438438 15 review team or the Illinois Fatality Review Team Advisory
439439 16 Council under Section 15 of the Adult Protective Services
440440 17 Act.
441441 18 (aa) Information which is exempted from disclosure
442442 19 under Section 2.37 of the Wildlife Code.
443443 20 (bb) Information which is or was prohibited from
444444 21 disclosure by the Juvenile Court Act of 1987.
445445 22 (cc) Recordings made under the Law Enforcement
446446 23 Officer-Worn Body Camera Act, except to the extent
447447 24 authorized under that Act.
448448 25 (dd) Information that is prohibited from being
449449 26 disclosed under Section 45 of the Condominium and Common
450450
451451
452452
453453
454454
455455 HB3256 - 12 - LRB103 27492 CPF 53866 b
456456
457457
458458 HB3256- 13 -LRB103 27492 CPF 53866 b HB3256 - 13 - LRB103 27492 CPF 53866 b
459459 HB3256 - 13 - LRB103 27492 CPF 53866 b
460460 1 Interest Community Ombudsperson Act.
461461 2 (ee) Information that is exempted from disclosure
462462 3 under Section 30.1 of the Pharmacy Practice Act.
463463 4 (ff) Information that is exempted from disclosure
464464 5 under the Revised Uniform Unclaimed Property Act.
465465 6 (gg) Information that is prohibited from being
466466 7 disclosed under Section 7-603.5 of the Illinois Vehicle
467467 8 Code.
468468 9 (hh) Records that are exempt from disclosure under
469469 10 Section 1A-16.7 of the Election Code.
470470 11 (ii) Information which is exempted from disclosure
471471 12 under Section 2505-800 of the Department of Revenue Law of
472472 13 the Civil Administrative Code of Illinois.
473473 14 (jj) Information and reports that are required to be
474474 15 submitted to the Department of Labor by registering day
475475 16 and temporary labor service agencies but are exempt from
476476 17 disclosure under subsection (a-1) of Section 45 of the Day
477477 18 and Temporary Labor Services Act.
478478 19 (kk) Information prohibited from disclosure under the
479479 20 Seizure and Forfeiture Reporting Act.
480480 21 (ll) Information the disclosure of which is restricted
481481 22 and exempted under Section 5-30.8 of the Illinois Public
482482 23 Aid Code.
483483 24 (mm) Records that are exempt from disclosure under
484484 25 Section 4.2 of the Crime Victims Compensation Act.
485485 26 (nn) Information that is exempt from disclosure under
486486
487487
488488
489489
490490
491491 HB3256 - 13 - LRB103 27492 CPF 53866 b
492492
493493
494494 HB3256- 14 -LRB103 27492 CPF 53866 b HB3256 - 14 - LRB103 27492 CPF 53866 b
495495 HB3256 - 14 - LRB103 27492 CPF 53866 b
496496 1 Section 70 of the Higher Education Student Assistance Act.
497497 2 (oo) Communications, notes, records, and reports
498498 3 arising out of a peer support counseling session
499499 4 prohibited from disclosure under the First Responders
500500 5 Suicide Prevention Act.
501501 6 (pp) Names and all identifying information relating to
502502 7 an employee of an emergency services provider or law
503503 8 enforcement agency under the First Responders Suicide
504504 9 Prevention Act.
505505 10 (qq) Information and records held by the Department of
506506 11 Public Health and its authorized representatives collected
507507 12 under the Reproductive Health Act.
508508 13 (rr) Information that is exempt from disclosure under
509509 14 the Cannabis Regulation and Tax Act.
510510 15 (ss) Data reported by an employer to the Department of
511511 16 Human Rights pursuant to Section 2-108 of the Illinois
512512 17 Human Rights Act.
513513 18 (tt) Recordings made under the Children's Advocacy
514514 19 Center Act, except to the extent authorized under that
515515 20 Act.
516516 21 (uu) Information that is exempt from disclosure under
517517 22 Section 50 of the Sexual Assault Evidence Submission Act.
518518 23 (vv) Information that is exempt from disclosure under
519519 24 subsections (f) and (j) of Section 5-36 of the Illinois
520520 25 Public Aid Code.
521521 26 (ww) Information that is exempt from disclosure under
522522
523523
524524
525525
526526
527527 HB3256 - 14 - LRB103 27492 CPF 53866 b
528528
529529
530530 HB3256- 15 -LRB103 27492 CPF 53866 b HB3256 - 15 - LRB103 27492 CPF 53866 b
531531 HB3256 - 15 - LRB103 27492 CPF 53866 b
532532 1 Section 16.8 of the State Treasurer Act.
533533 2 (xx) Information that is exempt from disclosure or
534534 3 information that shall not be made public under the
535535 4 Illinois Insurance Code.
536536 5 (yy) Information prohibited from being disclosed under
537537 6 the Illinois Educational Labor Relations Act.
538538 7 (zz) Information prohibited from being disclosed under
539539 8 the Illinois Public Labor Relations Act.
540540 9 (aaa) Information prohibited from being disclosed
541541 10 under Section 1-167 of the Illinois Pension Code.
542542 11 (bbb) Information that is prohibited from disclosure
543543 12 by the Illinois Police Training Act and the Illinois State
544544 13 Police Act.
545545 14 (ccc) Records exempt from disclosure under Section
546546 15 2605-304 of the Illinois State Police Law of the Civil
547547 16 Administrative Code of Illinois.
548548 17 (ddd) Information prohibited from being disclosed
549549 18 under Section 35 of the Address Confidentiality for
550550 19 Victims of Domestic Violence, Sexual Assault, Human
551551 20 Trafficking, or Stalking Act.
552552 21 (eee) Information prohibited from being disclosed
553553 22 under subsection (b) of Section 75 of the Domestic
554554 23 Violence Fatality Review Act.
555555 24 (fff) Images from cameras under the Expressway Camera
556556 25 Act. This subsection (fff) is inoperative on and after
557557 26 July 1, 2023.
558558
559559
560560
561561
562562
563563 HB3256 - 15 - LRB103 27492 CPF 53866 b
564564
565565
566566 HB3256- 16 -LRB103 27492 CPF 53866 b HB3256 - 16 - LRB103 27492 CPF 53866 b
567567 HB3256 - 16 - LRB103 27492 CPF 53866 b
568568 1 (ggg) Information prohibited from disclosure under
569569 2 paragraph (3) of subsection (a) of Section 14 of the Nurse
570570 3 Agency Licensing Act.
571571 4 (hhh) Information submitted to the Department of State
572572 5 Police in an affidavit or application for an assault
573573 6 weapon endorsement, assault weapon attachment endorsement,
574574 7 .50 caliber rifle endorsement, or .50 caliber cartridge
575575 8 endorsement under the Firearm Owners Identification Card
576576 9 Act.
577577 10 (iii) Information prohibited from being disclosed
578578 11 under Section 30 of the Affordable Drug Manufacturing Act.
579579 12 (Source: P.A. 101-13, eff. 6-12-19; 101-27, eff. 6-25-19;
580580 13 101-81, eff. 7-12-19; 101-221, eff. 1-1-20; 101-236, eff.
581581 14 1-1-20; 101-375, eff. 8-16-19; 101-377, eff. 8-16-19; 101-452,
582582 15 eff. 1-1-20; 101-466, eff. 1-1-20; 101-600, eff. 12-6-19;
583583 16 101-620, eff 12-20-19; 101-649, eff. 7-7-20; 101-652, eff.
584584 17 1-1-22; 101-656, eff. 3-23-21; 102-36, eff. 6-25-21; 102-237,
585585 18 eff. 1-1-22; 102-292, eff. 1-1-22; 102-520, eff. 8-20-21;
586586 19 102-559, eff. 8-20-21; 102-813, eff. 5-13-22; 102-946, eff.
587587 20 7-1-22; 102-1042, eff. 6-3-22; 102-1116, eff. 1-10-23.)
588588 21 Section 97. Severability. The provisions of this Act are
589589 22 severable under Section 1.31 of the Statute on Statutes.
590590 23 Section 99. Effective date. This Act takes effect July 1,
591591 24 2023.
592592
593593
594594
595595
596596
597597 HB3256 - 16 - LRB103 27492 CPF 53866 b